Contraindication Ladder - Pharmacodiagnostic Drug Interaction Framework
1 Knadler et al. 2011 — Duloxetine Clinical Pharmacokinetics and Drug Interactions
Full Citation:: Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clinical Pharmacokinetics. 2011;50(5):281–294. (Knadler et al. 2011) DOI:: 10.2165/11539240-000000000-00000 PMID:: 21366359 Study Design:: Comprehensive PK review (Eli Lilly, drug manufacturer) Key Findings::
- Fluvoxamine (CYP1A2 inhibitor) increases duloxetine AUC by 460% (90% CI 359–584) and Cmax by 141% (90% CI 93–200)
- CYP1A2 inhibition produces clinically significant duloxetine exposure increase — listed in prescribing information
- Smoking associated with 30% decrease in duloxetine concentration (CYP1A2 induction)
- Duloxetine is a moderate CYP2D6 inhibitor; duloxetine PK affected by CYP2D6 poor metabolizer status but to a lesser extentConclusion:: Fluvoxamine–duloxetine is a Level 2 (PK catastrophe) contraindicated combination. The ~5× increase in duloxetine exposure carries risk of serotonin syndrome, hepatotoxicity, and exaggerated adverse effects. Documented in FDA labeling. Certainty Assessment::
- *Quality:*: High (Clin Pharmacokinet; manufacturer data)
- *Sample:*: Formal PK interaction study
- *Replication:*: Confirmed in FDA prescribing information and Hanif 2023
- *Score:*: 0.802 Due Bruun et al. 2024 — LDN RCT in Fibromyalgia
Full Citation:: Due Bruun K, Christensen R, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Bye-Møller L, Holsgaard-Larsen A, Toft P. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology. 2024;6(1):e31–e39. (Due Bruun et al. 2024) DOI:: 10.1016/S2665-9913(23)00278-3 PMID:: 38258677 Study Design:: Single-centre double-blind RCT Sample Size:: n=99 women with fibromyalgia (LDN 6 mg n=49, placebo n=50) Key Findings::
- No significant between-group difference in pain intensity change (−0.34 points, p=0.27, Cohen's d 0.23)
- AEs in 84% LDN vs 86% placebo; discontinuation due to AEs: 8% vs 6%
- Memory signal (highest responder RR 1.67) did not reach significance as a 30% responder category in the secondary-outcome re-analysis [@Nielsen2026LDNFMResponder]Conclusion:: LDN was not superior to placebo for pain in fibromyalgia, and the exploratory memory signal was not significant as a responder category (Nielsen, Vaegter, and Due Bruun 2026). Provides safety characterization relevant to Level 1 — LDN antagonizes μ-opioid receptors, creating a pharmacodynamic contraindication with opioid agonists. Certainty Assessment::
- *Quality:*: High (Lancet Rheumatology)
- *Sample:*: Moderate (n=99)
- *Replication:*: Consistent with Yang 2023 systematic review
- *Score:*: 0.753 Yang et al. 2023 — LDN Systematic Review in Fibromyalgia
Full Citation:: Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB. The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. Journal of Pain Research. 2023;16:1017–1023. (Yang et al. 2023) DOI:: 10.2147/JPR.S395457 PMID:: 36974308 PMCID:: PMC10039621 Study Design:: Systematic review Sample Size:: n=9 studies (1 RCT, 2 case reports, 2 case series, 4 pilot trials) Key Findings::
- LDN effective for symptomatic management of fibromyalgia across heterogeneous studies
- 78% of included studies evaluated safety — no severe adverse events reported
- Evidence level limited; large-sample RCTs neededConclusion:: Provides the most comprehensive safety characterization of LDN. Primary contraindication risk with opioids is pharmacodynamic opposition, not intrinsic LDN toxicity. Certainty Assessment::
- *Quality:*: Medium (J Pain Res; heterogeneous small studies)
- *Sample:*: Aggregated across 9 studies
- *Replication:*: Consistent with Due Bruun 2024 and Patten 2018
- *Score:*: 0.604 Lipworth & Grove 1997 — Partial Beta-Adrenoceptor Agonist Activity
Full Citation:: Lipworth BJ, Grove A. Evaluation of partial beta-adrenoceptor agonist activity. British Journal of Clinical Pharmacology. 1997;43(1):9–14. (Lipworth and Grove 1997) DOI:: 10.1111/j.1365-2125.1997.tb00025.x PMID:: 9056046 Study Design:: Comprehensive review of pharmacological principles Key Findings::
- Partial β-AR agonist exhibits opposite agonist/antagonist activity depending on adrenergic tone
- In presence of exogenous full agonist, β2-AR partial agonist activity expressed as antagonism (e.g., salmeterol attenuating fenoterol responses)
- Reduction of exercise heart rate occurs to a lesser degree with BBs having partial agonist activityConclusion:: Establishes mechanistic basis for Level 1 (Receptor Antagonism). β-blockers + β2-agonists represent direct pharmacodynamic opposition at the receptor level — textbook pharmacology. Certainty Assessment::
- *Quality:*: High (Br J Clin Pharmacol, foundational review)
- *Sample:*: N/A (pharmacological principles)
- *Replication:*: Confirmed in all major pharmacology textbooks
- *Score:*: 0.555 Everly et al. 2004 — Beta-Blocker Underuse in Secondary Prevention of MI
Full Citation:: Everly MJ, Heaton PC, Cluxton RJ Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Annals of Pharmacotherapy. 2004;38(2):286–293. (Everly, Heaton, and Cluxton 2004) DOI:: 10.1345/aph.1C472 PMID:: 14742768 Study Design:: Systematic literature review Key Findings::
- Absolute BB contraindications: severe bradycardia, sick sinus syndrome, second-/third-degree AV block, severe LV dysfunction, active PVD with rest ischemia, or reactive airway disease requiring airway support
- Cardioselective β-blockers + albuterol can minimize bronchospasm effects
- BB use reduces mortality by 19–48% and reinfarction by up to 28%Conclusion:: Explicit clinical contraindication criteria support Level 1: non-cardioselective β-blockers block β2-mediated bronchodilation, opposing β2-agonist therapy. Certainty Assessment::
- *Quality:*: Medium (Ann Pharmacother)
- *Sample:*: N/A (review)
- *Replication:*: Consistent with all major guidelines
- *Score:*: 0.506 Blockmans et al. 2006 — Methylphenidate in CFS (RCT)
Full Citation:: Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? American Journal of Medicine. 2006;119(2):167.e23–167.e30. (Blockmans et al. 2006) DOI:: 10.1016/j.amjmed.2005.07.047 PMID:: 16443425 Study Design:: Double-blind crossover RCT Sample Size:: n=60 CFS (Fukuda 1994) Key Findings::
- Methylphenidate 2×10 mg/day significantly reduced fatigue vs placebo (CIS: −9.7, p `<` 0.0001; VAS: −1.0, p=0.001)
- Clinical significant effect in only 17% for fatigue, 22% for concentration — 83% non-response
- Did NOT assess PEM as outcomeConclusion:: Stimulants provide short-term benefit in a minority. The 83% non-response may reflect PEM exacerbation from activity masking. Supports Level 4 — stimulants in documented PEM carry risk of energy envelope violation. Certainty Assessment::
- *Quality:*: High (Am J Med, rigorous crossover)
- *Sample:*: Moderate (n=60)
- *Replication:*: Consistent with Van Houdenhove 2010, Eckey 2025
- *Score:*: 0.657 Blockmans and Persoons 2016 — Long-Term Methylphenidate Intake in CFS (observational follow-up)
Full Citation:: Blockmans D, Persoons P. Long-term methylphenidate intake in chronic fatigue syndrome. Acta Clinica Belgica. 2016;71(6):407–414. (Blockmans and Persoons 2016) DOI:: 10.1080/17843286.2016.1200816 PMID:: 27351244 Study Design:: Long-term observational follow-up (questionnaire) of the 2006 RCT cohort Sample Size:: 194 consecutive patients prescribed methylphenidate; 149 (76.8%) returned the questionnaire Key Findings::
- 65.3% had stopped methylphenidate by follow-up; 34.7% still took it daily or occasionally
- Among continuers: 48% reported ≥50% fatigue improvement; 62% reported ≥50% concentration improvement
- Continued intake was associated with more working hours
- Side effects (agitation, palpitations, dry mouth) reported significantly more by those who had stoppedConclusion:: Long-term benefit in about 1 in 3 patients. The high (65%) dropout rate is itself informative — consistent with the paper’s model that patients who stopped may have been those whose activity increased and PEM worsened, while continuers maintained pacing and gained cognitive benefit without PEM cost. Complements the 2006 RCT’s short-term 17%/22% response figure. Certainty Assessment::
- *Quality:*: Medium (observational, single-centre, self-reported)
- *Sample:*: Moderate (n=149)
- *Replication:*: Single study; consistent with the 2006 RCT responder pattern
- *Score:*: 0.558 Eckey et al. 2025 — Patient-Reported Treatment Outcomes in ME/CFS and Long COVID
Full Citation:: Eckey M, Li P, Morrison B, Bergquist J, Davis RW, Xiao W. Patient-reported treatment outcomes in ME/CFS and long COVID. Proceedings of the National Academy of Sciences. 2025;122(28):e2426874122. (Eckey et al. 2025) DOI:: 10.1073/pnas.2426874122 PMID:: 40627388 PMCID:: PMC12280984 Study Design:: Large patient survey Sample Size:: n=3,925 (ME/CFS and long COVID) Key Findings::
- 150+ treatments evaluated; 89.7% ME/CFS reported PEM
- POTS-dominant cluster benefited from autonomic modulators; cognitive-dysfunction cluster benefited from CNS stimulants
- Treatment responses correlated between ME/CFS and long COVID (R²=0.68)Conclusion:: Directly supports cluster-specific contraindications. CNS stimulants may be harmful in POTS-dominant ME/CFS (increased HR → PEM exacerbation). Differential cluster response is empirical basis for Level 4 stimulant contraindication. Certainty Assessment::
- *Quality:*: High (PNAS)
- *Sample:*: Large (n=3,925)
- *Replication:*: Consistent with Blockmans 2006
- *Score:*: 0.709 Ponticelli et al. 2023 — Autophagy and Podocytopathy
Full Citation:: Ponticelli C, Moroni G, Reggiani F. Autophagy and podocytopathy. Nephrology Dialysis Transplantation. 2023;38(9):1931–1939. (Ponticelli, Moroni, and Reggiani 2023) DOI:: 10.1093/ndt/gfad024 PMID:: 36708169 Study Design:: Narrative review Key Findings::
- Autophagy regulated by AMPK (activator) and mTOR (inhibitor)
- "Caution is needed with other autophagy activators, such as mTOR inhibitors and metformin, because of potential adverse events"
- No clinical trial with autophagy regulators in podocytopathies conductedConclusion:: Only identified paper warning about combined mTOR inhibitor + metformin use. Supports Level 4: rapamycin + metformin → dual-pathway mTORC1 suppression → potentially excessive autophagy → amplified PEM risk. Certainty Assessment::
- *Quality:*: Medium (NDT)
- *Sample:*: N/A (review)
- *Replication:*: Single cautionary statement; no trial data
- *Score:*: 0.4510 Kim & Farrell 2022 — Orthostatic Hypotension: A Practical Approach
Full Citation:: Kim MJ, Farrell J. Orthostatic Hypotension: A Practical Approach. American Family Physician. 2022;105(1):39–49. (Kim and Farrell 2022) PMID:: 35029940 Study Design:: Clinical review Key Findings::
- First-line OH medications: midodrine and droxidopa
- "Although fludrocortisone improves symptoms, it has concerning long-term effects"
- OH associated with up to 50% increase in all-cause mortalityConclusion:: Supports contraindication table: fludrocortisone worsening orthostasis → permanent avoidance. Volume expansion does not address structural venous pooling in connective-tissue-driven OH. Certainty Assessment::
- *Quality:*: Medium (Am Fam Physician)
- *Sample:*: N/A (review)
- *Replication:*: Consistent with Palma 2020
- *Score:*: 0.5511 Palma & Kaufmann 2020 — Management of Orthostatic Hypotension
Full Citation:: Palma JA, Kaufmann H. Management of Orthostatic Hypotension. Continuum (Minneapolis, Minn.). 2020;26(1):154–177. (Palma and Kaufmann 2020) DOI:: 10.1212/CON.0000000000000816 PMID:: 31996627 PMCID:: PMC7339914 Study Design:: Clinical review (AAN Continuum) Key Findings::
- Fludrocortisone associated with renal failure, cardiac failure, increased all-cause hospitalization
- Peripheral denervation → better droxidopa response; central dysfunction → better NE reuptake inhibitor responseConclusion:: Pharmacodiagnostic differentiation of OH type predicts drug response — aligns with ch34 framework. In connective-tissue-driven OH, fludrocortisone may worsen outcomes. Certainty Assessment::
- *Quality:*: High (Continuum — AAN flagship)
- *Sample:*: N/A (review)
- *Replication:*: Consistent with Kim 2022
- *Score:*: 0.6012 Dayal et al. 2025 — Clonidine + Midodrine in SH-OH (Case Report)
Full Citation:: Dayal M, Shah MS, Radfar N, Patel S, Thomas R. Multimodal Management of Supine Hypertension With Orthostatic Hypotension in an Elderly Male Patient With Parkinson’s Disease. Cureus. 2025;17(4):e82394. (Dayal et al. 2025) DOI:: 10.7759/cureus.82394 PMID:: 40385848 PMCID:: PMC12084856 Study Design:: Single case report Key Findings::
- Clonidine + hydralazine at bedtime for SH; midodrine timed around daytime activity for OH
- Temporal separation successfully managed opposing pharmacodynamic goalsConclusion:: Confirms Level 3 (PD Opposition): simultaneous clonidine + midodrine is self-negating, but temporal separation converts opposition into complementarity. Certainty Assessment::
- *Quality:*: Low (Cureus case report, n=1)
- *Sample:*: Single case
- *Replication:*: None
- *Score:*: 0.2513 Amariles et al. 2007 — Clinical Relevance of Drug Interactions
Full Citation:: Amariles P, Giraldo NA, Faus MJ. Clinical relevance of drug interactions. Medicina Clínica. 2007;129(1):27–35. (Amariles, Giraldo, and Faus 2007) DOI:: 10.1157/13106681 PMID:: 17570184 Study Design:: Narrative review [Spanish] Key Findings::
- Proposes DDI classification based on severity and probability of occurrence
- Emphasizes systemic clearance and bioavailability changes as key PK parametersConclusion:: Closest existing framework to DDI severity classification. Uses severity + probability rather than mechanism type — confirming the contraindication ladder’s novel organizational principle. Score:: 0.40
14 Dieu et al. 2019 — High-Risk DDI Prevalence in Paediatric Inpatients
Full Citation:: Dieu LW, Leuppi-Taegtmeyer AB, van den Anker J, Trachsel D, Gotta V. Prevalence of high-risk drug-drug interactions in paediatric inpatients: a retrospective, single-centre cohort analysis. Swiss Medical Weekly. 2019;149:w20103. (Dieu et al. 2019) DOI:: 10.4414/smw.2019.20103 PMID:: 31422575 Study Design:: Retrospective cohort analysis Sample Size:: n=300 paediatric inpatients Key Findings::
- Pharmavista CDSS uses "contraindicated" and "contraindicated by precaution" severity tiers
- Zero cases "contraindicated"; 1.7% "contraindicated by precaution"Conclusion:: Demonstrates existing severity-tiered DDI systems but none organize by mechanism type — confirming the ladder’s novelty. Score:: 0.55